Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + filgrastim
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
This is a combination of a placebo (an inert substance with no active pharmacological effect) and filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). Filgrastim stimulates the bone marrow to produce neutrophils, thereby reducing the risk and duration of neutropenia in patients undergoing chemotherapy or other treatments that suppress bone marrow function. The combination "placebo + filgrastim" typically refers to an arm in clinical trials where one group receives filgrastim and another receives placebo for comparison. Filgrastim is used primarily for preventing infection in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy, managing severe chronic neutropenia, mobilizing hematopoietic progenitor cells for collection by leukapheresis, aiding recovery after bone marrow transplantation, and improving survival after radiation exposure[1][2][3][6].
- Other names
- placebo + filgrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on placebo + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + filgrastim.